Symphony Financial Ltd. Co. Makes New $307,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Symphony Financial Ltd. Co. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,162 shares of the life sciences company’s stock, valued at approximately $307,000.

Several other large investors also recently modified their holdings of the stock. Brown Brothers Harriman & Co. increased its position in Illumina by 460.9% in the first quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after buying an additional 106 shares during the last quarter. State of Wyoming bought a new position in shares of Illumina during the 2nd quarter worth $32,000. Penserra Capital Management LLC purchased a new stake in Illumina in the 1st quarter worth about $64,000. ST Germain D J Co. Inc. purchased a new stake in Illumina during the second quarter valued at about $36,000. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in Illumina during the third quarter worth about $30,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ILMN. Wolfe Research initiated coverage on shares of Illumina in a research note on Wednesday, December 13th. They set an “outperform” rating and a $175.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Wednesday, February 14th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $258.00 price target on shares of Illumina in a report on Friday, February 9th. Finally, Bank of America lowered shares of Illumina from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $140.00 to $100.00 in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $166.95.

Illumina Trading Down 1.0 %

Illumina stock traded down $1.36 during mid-day trading on Friday, reaching $137.32. 917,083 shares of the company traded hands, compared to its average volume of 1,626,726. The firm’s 50 day moving average price is $138.46 and its 200 day moving average price is $129.43. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $233.42. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market capitalization of $21.82 billion, a price-to-earnings ratio of -18.71 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share. On average, analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.